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ic situation in Ukraine continues 
to deteriorate which is largely 
due to cardiovascular diseases 
significantly affecting the main 
indicators of public health. A 
constant increase in the total 
mortality of population and a 
decrease in life expectancy cause 
a serious concern and indicate a 
lack of effectiveness of preventive 
measures. Although circulatory 
system diseases are the leading 
cause of death in economically 
developed countries, there has 
been a steady positive trend in 
health indicators associated with 
this pathology in recent decades. 
At the same time, the opposite 
trend is observed in Ukraine: 
over the last 30 years, the preva-
lence of cardiovascular diseases 
among the population has in-
creased 3.5 times, and the associ-
ated mortality rate has grown by 
46 % [1–3].
The abovementioned factors 
prompted the creation of a funda-
mentally new domestic antiangi-
nal and antihypertensive drug. 
Scientists of the Scientific-Pro-
duction Association “Farmatron” 
jointly with the staff of the Phar- 
maceutical Chemistry Depart-
ment of Zaporizhzhia State Med-
ical University under the lead-
ership of Professor Mazur I. A. 
obtained a new original com-
pound – bromide 1-(β-phenyl-
ethyl)-4-amino-1,2,4-triazole 
(conditional name “Hypertril”), 
which exhibits antihypertensive, 
anti-ischemic and antioxidant 
properties [4, 5].
It is known that the quali-
ty of medicines largely depends 
on the degree of their purity. 
Therefore, a very important task 
of pharmaceutical analysis is to 
establish the purity of the drug 
because the presence of impuri-
ties affects its physicochemical 
properties, dosage, pharmacological effect, while contamina-
tion with toxic impurities makes the drug dangerous to human 
life and health. Therefore, the regulatory documentation and 
methods of drug quality control require tests for impurities.
Therefore, the aim of work was to develop a modern 
method to determine related impurities in tablets of bromide 
1-(β-phenylethyl)-4-amino-1,2,4-triazole.
2. Materials and Methods
We tried to use an already developed method of HPLC to de-
termine impurities in the obtained tablets of bromide 1-(β-pheny-
lethyl)-4-amino-1,2,4-triazole. 
The study proved that this meth-
od of impurity determination can 
be used not only for the analy- 
sis of bromide 1-(β-phenylethyl)- 
4-amino-1,2,4-triazole and in- 
jectable solutions, but also for tab-
lets. That is why we have devel-
oped a HPLC method for the de-
termination of related impurities 
in tablets of bromide 1-(β-phenyl-
ethyl)-4-amino-1,2,4-triazole [6, 7].
The related impurities of 
4-amino-1,2,4-triazole in tablets 
of bromide 1-(ß-phenylethyl)-4- 
amino-1,2,4-triazole were deter-
mined by HPLC.
Test solution (a). 1.0 g of 
powdered tablets is placed in a 
25.00 ml volumetric f lask and 
made up to the mark with water. 
The thoroughly mixed solution 
is filtered through a filter with a 
pore diameter of not more than 
0.45 μm.
Test solution (b). 5 ml of the 
filtrate are placed in a 10.00 ml 
volumetric flask and made up to 
the mark with eluent.
Comparison solution (a). 25 mg 
of 4-amino-1,2,4-triazole are dis-
solved in 10 ml of eluent and 
made up to 25 ml with eluent.
Comparison solution (b). 20 mg 
of pharmacopoeial standard sam- 
ple of bromide 1-(β-phenylethyl)- 
4-amino-1,2,4-triazole are placed 
in a 10.00 ml volumetric flask, 
dissolved in 5 ml of purified wa-
ter, 0.1 ml of comparison solu- 
tion (a) is added and made up to 
the mark with eluent.
Chromatography was carried 
out under the following condi-
tions:
– HypersilODS (C18) 5 u, 
4.6×250 mm, column, particle 
diameter of 5 μm.
– mobile phase: mixture 
(10:90 vol. %) of acetonitrile and 
phosphate buffer pH 3.0 contain-
ing ion-vapor reagent: 3.6 g of 
Na2HPO4 and 3.4 g of Bu4NHSO4 
were dissolved in 900 ml of distilled water, orthophosphoric 
acid was added to pH 3.0, followed by 100 ml of acetonitrile:
– mobile phase rate: 1 ml/min;
– analytical wavelength of the detector: 220 nm;
– sample volume: 20 μl
3. Results
In order to reach reliable results, the test solution (b) and 
the comparison solution (b) (Fig. 1, 2) were alternately chro-
matographed to obtain at least three chromatograms for each 
solution.
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Abstract: Aim: to develop a modern method to determine 
related impurities in bromide 1-(β-phenylethyl)-4-amino- 
1,2,4-triazole tablets by high performance liquid chromatog-
raphy (HPLC).
Methods: The development of a method to determine related 
impurities in bromide 1-(β-phenylethyl)-4-amino-1,2,4-tri-
azole tablets involved an already developed method for the 
determination of 4-amino-1,2,4-triazole impurities in tablets 
by HPLC. The test solution and the comparison solution were 
prepared and chromatographed alternately according to the 
developed methods. At least three chromatograms were ob-
tained for each solution for the purpose of the reliability of the 
study results.
Results: Scientists of the Scientific-Production Associa-
tion "Farmatron" jointly with the staff of the Pharmaceutical 
Chemistry Department of Zaporizhzhia State Medical Uni-
versity under the leadership of Professor Mazur I. A. obtained 
a new original compound – bromide 1-(β-phenylethyl)-4- 
amino-1,2,4-triazole (conditional name "Hypertril"), which 
exhibits antihypertensive, anti-ischemic and antioxidant prop-
erties. It is known that the quality of medicines largely depends 
on the degree of their purity. Therefore, in accordance with 
the regulatory documentation and quality control methods 
of medicines, it is mandatory to carry out tests for impurities. 
According to the results, the content of impurities of 4-amino- 
1,2,4-triazole in the tested tablets of bromide 1-(β-phenyle-
thyl)-4-amino-1,2,4-triazole is in the range from 0.049 % to 
0.195 % which meets the requirements of regulatory docu-
mentation. No peaks of unidentified impurities were detected 
on the chromatograms of the test solution.
Conclusion: Therefore, a modern method to determine the re-
lated impurity of 4-amino-1,2,4-triazole in tablets of bromide 
1-(β-phenylethyl)-4-amino-1,2,4-triazole has been developed. 
The methodology is reproducible, accurate and meets the re-
quirements of regulatory documentation.
Keywords: tablets, bromide 1-(β-phenylethyl)-4-amino-1,2,4- 
triazolium, accompanying impurities, HPLC method, chro-
matogram, coronary heart disease, arterial hypertension.
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Fig. 1. Test solution chromatogram (b)
Fig. 2. Comparison solution chromatogram (b)
The analysis results are considered significant if the follow-
ing conditions are met:
– the relative standard deviation of the peak areas of 
4-amino-1,2,4-triazole, calculated on the basis of the chromato-
grams of the comparison solution, must meet the requirements 
of regulatory documentation;
– the efficiency of the chromatographic system, calculated by 
the peak of 4-amino-1,2,4-triazole from the chromatograms of 
the comparison solution, must be at least 1500 theoretical plates;
– the capacity factor calculated from the peak of 4-amino- 
1,2,4-triazole must be at least 0.5. The wavefront time of the 
first peak (bromide 1-(β-phenylethyl)-4-amino-1,2,4-triazoli-
um) on the chromatogram of the test solution (retention time 
is about 2 minutes) is taken as the peak of the substance that is 
not retained.
The results of the study are presented in Table 1. It is seen 
that the impurity content of 4-amino-1,2,4-triazole in the tested 
tablets of bromide 1-(β-phenylethyl)-4-amino-1,2,4-triazole is 
within from 0.049 % to 0.195 %, that meets the requirements 
of regulatory documentation. The chromatograms of the test 
solution showed no peaks of unidentified impurities.
4. Discussion 
As a result of previous studies, a new original tablet drug 
“Hypertril” with the active substance of bromide 1-(β-phenyl-
ethyl)-4-amino-1,2,4-triazole 20 mg was created.
It is known that the purity of medicines is an important 
aspect in ensuring their quality. That’s why, the next step of our 
research team was to develop a determination method for the 
related impurities in the created tablets of 1-(β-phenylethyl)-4- 
amino-1,2,4-triazole bromide. To that end, we chose the method 
of HPLC, which is widely used for standardization of drugs due to 
its high sensitivity, specificity and rapidity of analysis.
The experimental studies results indicate that, for the first 
time, we have developed a rational method for determining the 
related impurity of 4-amino-1,2,4-triazole, which proved to be 
reproducible and accurate. Consequently, it can be applied in 
standardization of the “Hypertril” drug in terms of the “Pu-
rity” indicator. Therefore, it provided for the first inclusion 
of this technique in the draft analytical document – quality 
control methods for tablets of bromide 1-(β-phenylethyl)-4- 
amino-1,2,4-triazole under the conditional name of “Hypertril”.



















Results of determining the content of impurities in bromide 1-(β-phenylethyl)-4-amino-1,2,4-triazole tablets
Series No. 4-Amino-1,2,4-triazole peak area, mV.sec
4-Amino-1,2,4-triazole mean peak 
area, mV.sec
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 A set of biological studies permitted to determine the phar-
macological characteristics of tablets of bromide 1-(β-pheny-
lethyl)-4-amino-1,2,4-triazolium which made it possible to 
classify the drug as toxicity class IV (low-toxic substances). All 
our studies prove that the new original tablet drug “Hypertril” is 
a promising antihypertensive and antianginal drug [8–10], and 
the developed methods of its standardization are also reliable.
The limitations of the study. The development of the 
study design involved some difficulties, since the tablets were 
created on the basis of a new substance – bromide 1-(β-phenyl-
ethyl)-4-amino-1,2,4-triazole. These tablets are also being pre-
pared for clinical trials, so it is necessary to obtain a trial batch 
in an industrial setting. A prerequisite for this is the develop-
ment of a specification that includes the “Purity” parameter. All 
these problems have been resolved in the course of the research.
The perspectives for further studies. It is planned to use 
the developed method in order to create specifications for “Hy-
pertril” tablets, as well as to make adaptations for the purpose 
of quality control of other dosage forms on the basis of bromide 
1-(β-phenylethyl)-4-amino-1,2,4-triazole.
5. Сonclusions
In the course of the previously conduced experimental stud-
ies, a tablet dosage form based on bromide 1-(β-phenylethyl)- 
4-amino-1, 2, 4-triazolium has been developed. The drug pro-
duces antihypertensive and anti-ischemic action. According 
to the regulations and quality control methods of medicines, 
tests for impurities are mandatory. Thus, we have devel-
oped a modern method to determine the related impurity of 
4-amino-1,2,4-triazole in tablets of bromide 1-(β-phenylethyl)- 
4-amino-1,2,4-triazole using HPLC. The developed method-
ology is reproducible, accurate and meets the requirements of 
regulatory documents.
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